Boehringer Ingelheim and Sanofi enter into contract manufacturing alliance


To produce monoclonal antibodies for global market supply

Boehringer Ingelheim has signed a deal with Sanofi under which the German company's cell culture operations will provide contract manufacturing to support the French drugmaker's biologics pipeline.

Sign up for your free email newsletter

Under the terms of the agreement, Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin early this year.